Eisai To Test Alzheimer's Drug On Young Down Syndrome Patients
This article was originally published in PharmAsia News
Eisai said it plans to launch clinical trials in August to test its Aricept (donepezil) Alzheimer's disease drug for the additional use in aiding the social abilities of persons with Down syndrome.
You may also be interested in...
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.